Peluso, MJ, Lewis, SW, Barnes, TRE, Jones, PB.
Extrapyramidal motor side–effects of first–and
second-generation antipsychotic drugs. Br J
2012; 200: 387–92.
Jones, PB, Barnes, TR, Davies, L, Dunn, G, Lloyd, H, Hayhurst, KP, . Randomized controlled
trial of the effect on Quality of Life of second– vs first–generation
antipsychotic drugs in schizophrenia: Cost Utility of the Latest
Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
Arch Gen Psychiatry
2006; 63: 1079–87.
Jones, PB, Barnes, TRE, Elton, P, Davies, L, Dunn, G, Lloyd, H,
First– vs second–generation antipsychotic drugs in
schizophrenia - reply. Arch Gen
2007; 64: 979–80.
Soares, BG, Fenton, M, Chue, P.
Sulpiride for schizophrenia. Cochrane
Database Syst Rev
Weizman, A, Maoz, B, Treves, I, Asher, I, Ben David, M.
Sulpiride–induced hyperprolactinemia and impotence in male
psychiatric outpatients. Prog
Neuropsychopharmacology Biol Psychiatry
1985; 9: 193–8.
Schoemaker, H, Claustre, Y, Fage, D, Rouquier, L, Chergui, K, Curet, O,
Neurochemical characteristics of amisulpride, an atypical
dopamine D2/D3 receptor antagonist with both presynaptic and limbic
selectivity. J Pharmacol Exp Ther
1997; 280: 183–97.
The controversy of significance testing: misconceptions and
alternatives. Am J Crit Care
1999; 8: 291–6.